| 48.72 -0.84 (-1.69%) | 08-28 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 60.4 | 1-year : | 70.55 |
| Resists | First : | 51.71 | Second : | 60.4 |
| Pivot price | 48.06  |
|||
| Supports | First : | 41.59 | Second : | 35.34 |
| MAs | MA(5) : | 49.54 |
MA(20) : | 47.23 |
| MA(100) : | 34.02 |
MA(250) : | 30.81 |
|
| MACD | MACD : | 2.1  |
Signal : | 2.1 |
| %K %D | K(14,3) : | 73.7 |
D(3) : | 80.4 |
| RSI | RSI(14): 59 |
|||
| 52-week | High : | 71.5 | Low : | 8.72 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ QURE ] has closed below upper band by 40.6%. Bollinger Bands are 39.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 49.56 - 49.97 | 49.97 - 50.24 |
| Low: | 47.56 - 48.01 | 48.01 - 48.31 |
| Close: | 48.14 - 48.83 | 48.83 - 49.29 |
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Fri, 28 Aug 2026
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
Fri, 28 Aug 2026
Why Is uniQure (QURE) Up 17.5% Since Last Earnings Report? - Yahoo Finance
Tue, 25 Aug 2026
uniQure (QURE) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Sat, 22 Aug 2026
Price to sales forward of uniQure N.V. – NASDAQ:QURE - TradingView
Fri, 14 Aug 2026
Susquehanna entities (QURE) disclose 3.34M-share, 4.8% position in uniQure - Stock Titan
Fri, 14 Aug 2026
RTW Investments (QURE) discloses 3.94M-share beneficial stake in uniQure N.V. - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 69 (M) |
| Shares Float | 58 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 97.7 (%) |
| Shares Short | 10,680 (K) |
| Shares Short P.Month | 11,490 (K) |
| EPS | -4.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.67 |
| Profit Margin | 0 % |
| Operating Margin | -872.3 % |
| Return on Assets (ttm) | -15.8 % |
| Return on Equity (ttm) | -157.7 % |
| Qtrly Rev. Growth | 11 % |
| Gross Profit (p.s.) | -1.66 |
| Sales Per Share | 0.26 |
| EBITDA (p.s.) | -2.64 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -161 (M) |
| Levered Free Cash Flow | -78 (M) |
| PE Ratio | -12 |
| PEG Ratio | 0 |
| Price to Book value | 10.43 |
| Price to Sales | 181.02 |
| Price to Cash Flow | -21.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|